interferon 1b recombinant human interferon beta (Boster Bio)
Boster Bio is a verified supplier 
Boster Bio manufactures this product 
91
Structured Review
Boster Bio
interferon 1b recombinant human interferon beta
Interferon 1b Recombinant Human Interferon Beta, supplied by Boster Bio, used in various techniques. Bioz Stars score: 91/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/interferon+1b+recombinant+human+interferon+beta/Human+recombinant+IFN+alpha+1a+(Interferon+alpha+1a)+protein%2C+AF/pm35948371-133-231-279
Average 91 stars, based on 3 article reviews
Interferon 1b Recombinant Human Interferon Beta, supplied by Boster Bio, used in various techniques. Bioz Stars score: 91/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/interferon+1b+recombinant+human+interferon+beta/Human+recombinant+IFN+alpha+1a+(Interferon+alpha+1a)+protein%2C+AF/pm35948371-133-231-279
Average 91 stars, based on 3 article reviews
interferon 1b recombinant human interferon beta - by Bioz Stars,
2026-09
91/100 stars
Images
Related Articles
Binding Assay:Article Title: Neurodegeneration in multiple sclerosis. Article Snippet: Macrophages and microglia contain engulfed fragments of minor and major TABLE 1 Disease-modifying therapies for the treatment of MS DMT Proposed mechanisms of action References High efficacy Natalizumab Humanized monoclonal antibody binding to α4β1integrin; prevents leukocyte infiltration into CNS Miller et al. (2007); Yednock et al. (1992) Alemtuzumab Humanized monoclonal antibody binding to CD52 on T and B lymphocytes; depletes from circulation Cohen et al. (2012); Hu et al. (2009) Ocrelizumab, ofatumumab, rituximab Humanized, human, or chimeric monoclonal antibodies binding to CD20 on B lymphocytes; depletes from circulation Chisari et al. (2022); Hauser et al. (2016); Hauser et al. (2020); Montalvao et al. (2013) Moderate efficacy Fingolimod, siponimod, ozanimod, posanimod Structural analog to sphingosine; competitive inhibitor for sphingosine-1-phosphate; reduces lymphocyte egress into circulation Behrangi et al. (2019); Calabresi et al. (2014); McGinley and Cohen (2021); Mehling et al. (2008); Pinschewer et al. (2000) Cladribine Structural analog to adenosine; competitive inhibitor for adenosine deaminase; disrupts DNA synthesis and repair, leads to preferential T and B lymphocyte depletion Carson et al. (1983); Giovannoni et al. (2010); Leist et al. (2014); Seto et al. (1985) Dimethyl fumarate, diroximel fumarate Promotes anti-oxidant activity in CNS and periphery by Nrf2 activation; reduces overall T and B cell numbers in circulation; reduces lymphocyte maturation and activation Fox et al. (2012); Gold et al. (2012); Mills et al. (2018); Spencer et al. (2015) Low efficacy Interferon beta-1a and interferon-1b Recombinant human interferon-beta; increases antiinflammatory and decreases proinflammatory signaling by peripheral immune cells Dubois et al. (2003); Filipi & Jack (2020); Kieseier (2011) Glatiramer acetate Competes with MHC and TCR binding, thereby reducing inflammatory signaling; reduces proinflammatory signaling by inducing a shift toward Bioprocessing:Article Title: Neurodegeneration in multiple sclerosis. Article Snippet: Macrophages and microglia contain engulfed fragments of minor and major TABLE 1 Disease-modifying therapies for the treatment of MS DMT Proposed mechanisms of action References High efficacy Natalizumab Humanized monoclonal antibody binding to α4β1integrin; prevents leukocyte infiltration into CNS Miller et al. (2007); Yednock et al. (1992) Alemtuzumab Humanized monoclonal antibody binding to CD52 on T and B lymphocytes; depletes from circulation Cohen et al. (2012); Hu et al. (2009) Ocrelizumab, ofatumumab, rituximab Humanized, human, or chimeric monoclonal antibodies binding to CD20 on B lymphocytes; depletes from circulation Chisari et al. (2022); Hauser et al. (2016); Hauser et al. (2020); Montalvao et al. (2013) Moderate efficacy Fingolimod, siponimod, ozanimod, posanimod Structural analog to sphingosine; competitive inhibitor for sphingosine-1-phosphate; reduces lymphocyte egress into circulation Behrangi et al. (2019); Calabresi et al. (2014); McGinley and Cohen (2021); Mehling et al. (2008); Pinschewer et al. (2000) Cladribine Structural analog to adenosine; competitive inhibitor for adenosine deaminase; disrupts DNA synthesis and repair, leads to preferential T and B lymphocyte depletion Carson et al. (1983); Giovannoni et al. (2010); Leist et al. (2014); Seto et al. (1985) Dimethyl fumarate, diroximel fumarate Promotes anti-oxidant activity in CNS and periphery by Nrf2 activation; reduces overall T and B cell numbers in circulation; reduces lymphocyte maturation and activation Fox et al. (2012); Gold et al. (2012); Mills et al. (2018); Spencer et al. (2015) Low efficacy Interferon beta-1a and interferon-1b Recombinant human interferon-beta; increases antiinflammatory and decreases proinflammatory signaling by peripheral immune cells Dubois et al. (2003); Filipi & Jack (2020); Kieseier (2011) Glatiramer acetate Competes with MHC and TCR binding, thereby reducing inflammatory signaling; reduces proinflammatory signaling by inducing a shift toward DNA Synthesis:Article Title: Neurodegeneration in multiple sclerosis. Article Snippet: Macrophages and microglia contain engulfed fragments of minor and major TABLE 1 Disease-modifying therapies for the treatment of MS DMT Proposed mechanisms of action References High efficacy Natalizumab Humanized monoclonal antibody binding to α4β1integrin; prevents leukocyte infiltration into CNS Miller et al. (2007); Yednock et al. (1992) Alemtuzumab Humanized monoclonal antibody binding to CD52 on T and B lymphocytes; depletes from circulation Cohen et al. (2012); Hu et al. (2009) Ocrelizumab, ofatumumab, rituximab Humanized, human, or chimeric monoclonal antibodies binding to CD20 on B lymphocytes; depletes from circulation Chisari et al. (2022); Hauser et al. (2016); Hauser et al. (2020); Montalvao et al. (2013) Moderate efficacy Fingolimod, siponimod, ozanimod, posanimod Structural analog to sphingosine; competitive inhibitor for sphingosine-1-phosphate; reduces lymphocyte egress into circulation Behrangi et al. (2019); Calabresi et al. (2014); McGinley and Cohen (2021); Mehling et al. (2008); Pinschewer et al. (2000) Cladribine Structural analog to adenosine; competitive inhibitor for adenosine deaminase; disrupts DNA synthesis and repair, leads to preferential T and B lymphocyte depletion Carson et al. (1983); Giovannoni et al. (2010); Leist et al. (2014); Seto et al. (1985) Dimethyl fumarate, diroximel fumarate Promotes anti-oxidant activity in CNS and periphery by Nrf2 activation; reduces overall T and B cell numbers in circulation; reduces lymphocyte maturation and activation Fox et al. (2012); Gold et al. (2012); Mills et al. (2018); Spencer et al. (2015) Low efficacy Interferon beta-1a and interferon-1b Recombinant human interferon-beta; increases antiinflammatory and decreases proinflammatory signaling by peripheral immune cells Dubois et al. (2003); Filipi & Jack (2020); Kieseier (2011) Glatiramer acetate Competes with MHC and TCR binding, thereby reducing inflammatory signaling; reduces proinflammatory signaling by inducing a shift toward Activity Assay:Article Title: Neurodegeneration in multiple sclerosis. Article Snippet: Macrophages and microglia contain engulfed fragments of minor and major TABLE 1 Disease-modifying therapies for the treatment of MS DMT Proposed mechanisms of action References High efficacy Natalizumab Humanized monoclonal antibody binding to α4β1integrin; prevents leukocyte infiltration into CNS Miller et al. (2007); Yednock et al. (1992) Alemtuzumab Humanized monoclonal antibody binding to CD52 on T and B lymphocytes; depletes from circulation Cohen et al. (2012); Hu et al. (2009) Ocrelizumab, ofatumumab, rituximab Humanized, human, or chimeric monoclonal antibodies binding to CD20 on B lymphocytes; depletes from circulation Chisari et al. (2022); Hauser et al. (2016); Hauser et al. (2020); Montalvao et al. (2013) Moderate efficacy Fingolimod, siponimod, ozanimod, posanimod Structural analog to sphingosine; competitive inhibitor for sphingosine-1-phosphate; reduces lymphocyte egress into circulation Behrangi et al. (2019); Calabresi et al. (2014); McGinley and Cohen (2021); Mehling et al. (2008); Pinschewer et al. (2000) Cladribine Structural analog to adenosine; competitive inhibitor for adenosine deaminase; disrupts DNA synthesis and repair, leads to preferential T and B lymphocyte depletion Carson et al. (1983); Giovannoni et al. (2010); Leist et al. (2014); Seto et al. (1985) Dimethyl fumarate, diroximel fumarate Promotes anti-oxidant activity in CNS and periphery by Nrf2 activation; reduces overall T and B cell numbers in circulation; reduces lymphocyte maturation and activation Fox et al. (2012); Gold et al. (2012); Mills et al. (2018); Spencer et al. (2015) Low efficacy Interferon beta-1a and interferon-1b Recombinant human interferon-beta; increases antiinflammatory and decreases proinflammatory signaling by peripheral immune cells Dubois et al. (2003); Filipi & Jack (2020); Kieseier (2011) Glatiramer acetate Competes with MHC and TCR binding, thereby reducing inflammatory signaling; reduces proinflammatory signaling by inducing a shift toward Activation Assay:Article Title: Neurodegeneration in multiple sclerosis. Article Snippet: Macrophages and microglia contain engulfed fragments of minor and major TABLE 1 Disease-modifying therapies for the treatment of MS DMT Proposed mechanisms of action References High efficacy Natalizumab Humanized monoclonal antibody binding to α4β1integrin; prevents leukocyte infiltration into CNS Miller et al. (2007); Yednock et al. (1992) Alemtuzumab Humanized monoclonal antibody binding to CD52 on T and B lymphocytes; depletes from circulation Cohen et al. (2012); Hu et al. (2009) Ocrelizumab, ofatumumab, rituximab Humanized, human, or chimeric monoclonal antibodies binding to CD20 on B lymphocytes; depletes from circulation Chisari et al. (2022); Hauser et al. (2016); Hauser et al. (2020); Montalvao et al. (2013) Moderate efficacy Fingolimod, siponimod, ozanimod, posanimod Structural analog to sphingosine; competitive inhibitor for sphingosine-1-phosphate; reduces lymphocyte egress into circulation Behrangi et al. (2019); Calabresi et al. (2014); McGinley and Cohen (2021); Mehling et al. (2008); Pinschewer et al. (2000) Cladribine Structural analog to adenosine; competitive inhibitor for adenosine deaminase; disrupts DNA synthesis and repair, leads to preferential T and B lymphocyte depletion Carson et al. (1983); Giovannoni et al. (2010); Leist et al. (2014); Seto et al. (1985) Dimethyl fumarate, diroximel fumarate Promotes anti-oxidant activity in CNS and periphery by Nrf2 activation; reduces overall T and B cell numbers in circulation; reduces lymphocyte maturation and activation Fox et al. (2012); Gold et al. (2012); Mills et al. (2018); Spencer et al. (2015) Low efficacy Interferon beta-1a and interferon-1b Recombinant human interferon-beta; increases antiinflammatory and decreases proinflammatory signaling by peripheral immune cells Dubois et al. (2003); Filipi & Jack (2020); Kieseier (2011) Glatiramer acetate Competes with MHC and TCR binding, thereby reducing inflammatory signaling; reduces proinflammatory signaling by inducing a shift toward Recombinant:Article Title: Neurodegeneration in multiple sclerosis. Article Snippet: Macrophages and microglia contain engulfed fragments of minor and major TABLE 1 Disease-modifying therapies for the treatment of MS DMT Proposed mechanisms of action References High efficacy Natalizumab Humanized monoclonal antibody binding to α4β1integrin; prevents leukocyte infiltration into CNS Miller et al. (2007); Yednock et al. (1992) Alemtuzumab Humanized monoclonal antibody binding to CD52 on T and B lymphocytes; depletes from circulation Cohen et al. (2012); Hu et al. (2009) Ocrelizumab, ofatumumab, rituximab Humanized, human, or chimeric monoclonal antibodies binding to CD20 on B lymphocytes; depletes from circulation Chisari et al. (2022); Hauser et al. (2016); Hauser et al. (2020); Montalvao et al. (2013) Moderate efficacy Fingolimod, siponimod, ozanimod, posanimod Structural analog to sphingosine; competitive inhibitor for sphingosine-1-phosphate; reduces lymphocyte egress into circulation Behrangi et al. (2019); Calabresi et al. (2014); McGinley and Cohen (2021); Mehling et al. (2008); Pinschewer et al. (2000) Cladribine Structural analog to adenosine; competitive inhibitor for adenosine deaminase; disrupts DNA synthesis and repair, leads to preferential T and B lymphocyte depletion Carson et al. (1983); Giovannoni et al. (2010); Leist et al. (2014); Seto et al. (1985) Dimethyl fumarate, diroximel fumarate Promotes anti-oxidant activity in CNS and periphery by Nrf2 activation; reduces overall T and B cell numbers in circulation; reduces lymphocyte maturation and activation Fox et al. (2012); Gold et al. (2012); Mills et al. (2018); Spencer et al. (2015) Low efficacy Interferon beta-1a and interferon-1b Recombinant human interferon-beta; increases antiinflammatory and decreases proinflammatory signaling by peripheral immune cells Dubois et al. (2003); Filipi & Jack (2020); Kieseier (2011) Glatiramer acetate Competes with MHC and TCR binding, thereby reducing inflammatory signaling; reduces proinflammatory signaling by inducing a shift toward Immunopeptidomics:Article Title: Neurodegeneration in multiple sclerosis. Article Snippet: Macrophages and microglia contain engulfed fragments of minor and major TABLE 1 Disease-modifying therapies for the treatment of MS DMT Proposed mechanisms of action References High efficacy Natalizumab Humanized monoclonal antibody binding to α4β1integrin; prevents leukocyte infiltration into CNS Miller et al. (2007); Yednock et al. (1992) Alemtuzumab Humanized monoclonal antibody binding to CD52 on T and B lymphocytes; depletes from circulation Cohen et al. (2012); Hu et al. (2009) Ocrelizumab, ofatumumab, rituximab Humanized, human, or chimeric monoclonal antibodies binding to CD20 on B lymphocytes; depletes from circulation Chisari et al. (2022); Hauser et al. (2016); Hauser et al. (2020); Montalvao et al. (2013) Moderate efficacy Fingolimod, siponimod, ozanimod, posanimod Structural analog to sphingosine; competitive inhibitor for sphingosine-1-phosphate; reduces lymphocyte egress into circulation Behrangi et al. (2019); Calabresi et al. (2014); McGinley and Cohen (2021); Mehling et al. (2008); Pinschewer et al. (2000) Cladribine Structural analog to adenosine; competitive inhibitor for adenosine deaminase; disrupts DNA synthesis and repair, leads to preferential T and B lymphocyte depletion Carson et al. (1983); Giovannoni et al. (2010); Leist et al. (2014); Seto et al. (1985) Dimethyl fumarate, diroximel fumarate Promotes anti-oxidant activity in CNS and periphery by Nrf2 activation; reduces overall T and B cell numbers in circulation; reduces lymphocyte maturation and activation Fox et al. (2012); Gold et al. (2012); Mills et al. (2018); Spencer et al. (2015) Low efficacy Interferon beta-1a and interferon-1b Recombinant human interferon-beta; increases antiinflammatory and decreases proinflammatory signaling by peripheral immune cells Dubois et al. (2003); Filipi & Jack (2020); Kieseier (2011) Glatiramer acetate Competes with MHC and TCR binding, thereby reducing inflammatory signaling; reduces proinflammatory signaling by inducing a shift toward Expressing:Article Title: Neurodegeneration in multiple sclerosis. Article Snippet: Macrophages and microglia contain engulfed fragments of minor and major TABLE 1 Disease-modifying therapies for the treatment of MS DMT Proposed mechanisms of action References High efficacy Natalizumab Humanized monoclonal antibody binding to α4β1integrin; prevents leukocyte infiltration into CNS Miller et al. (2007); Yednock et al. (1992) Alemtuzumab Humanized monoclonal antibody binding to CD52 on T and B lymphocytes; depletes from circulation Cohen et al. (2012); Hu et al. (2009) Ocrelizumab, ofatumumab, rituximab Humanized, human, or chimeric monoclonal antibodies binding to CD20 on B lymphocytes; depletes from circulation Chisari et al. (2022); Hauser et al. (2016); Hauser et al. (2020); Montalvao et al. (2013) Moderate efficacy Fingolimod, siponimod, ozanimod, posanimod Structural analog to sphingosine; competitive inhibitor for sphingosine-1-phosphate; reduces lymphocyte egress into circulation Behrangi et al. (2019); Calabresi et al. (2014); McGinley and Cohen (2021); Mehling et al. (2008); Pinschewer et al. (2000) Cladribine Structural analog to adenosine; competitive inhibitor for adenosine deaminase; disrupts DNA synthesis and repair, leads to preferential T and B lymphocyte depletion Carson et al. (1983); Giovannoni et al. (2010); Leist et al. (2014); Seto et al. (1985) Dimethyl fumarate, diroximel fumarate Promotes anti-oxidant activity in CNS and periphery by Nrf2 activation; reduces overall T and B cell numbers in circulation; reduces lymphocyte maturation and activation Fox et al. (2012); Gold et al. (2012); Mills et al. (2018); Spencer et al. (2015) Low efficacy Interferon beta-1a and interferon-1b Recombinant human interferon-beta; increases antiinflammatory and decreases proinflammatory signaling by peripheral immune cells Dubois et al. (2003); Filipi & Jack (2020); Kieseier (2011) Glatiramer acetate Competes with MHC and TCR binding, thereby reducing inflammatory signaling; reduces proinflammatory signaling by inducing a shift toward |
